BRIGHTSURF

Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC

02.08.16 | Pharmamar

Nikon Monarch 5 8x42 Binoculars

Nikon Monarch 5 8x42 Binoculars deliver bright, sharp views for wildlife surveys, eclipse chases, and quick star-field scans at dark sites.

PharmaMar (MSE:PHM) announced today that the Independent Data Monitoring Committee (IDMC) has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.

The IDMC's recommendation came after an analysis of the safety data obtained with the first 80 patients treated in the trial. This pivotal randomised Phase III trial assesses the efficacy of PM1183 compared with the standard treatment for this indication -- topotecan or pegylated liposomal doxorubicin -- in a total of 420 patients.

###

Keywords

Drug Studies Ovarian Cancer Phase Transitions

Contact Information

Paula Fernández

Pharmamar

pfalarcon@pharmamar.com

Source

Original Source

http://www.pharmamar.com/wp-content/uploads/2016/02/PR_Positive-recommendation-IDMC.pdf

How to Cite This Article

APA:

Pharmamar. (2016, February 8). Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC. Brightsurf News. https://www.brightsurf.com/news/8XG2DEY1/phase-3-trial-with-pm1183-in-oc-continues-on-the-basis-of-positive-recommendation-by-idmc.html

MLA:

"Phase 3 trial with PM1183 in OC continues on the basis of positive recommendation by IDMC." Brightsurf News, Feb. 8 2016, https://www.brightsurf.com/news/8XG2DEY1/phase-3-trial-with-pm1183-in-oc-continues-on-the-basis-of-positive-recommendation-by-idmc.html.